Comparison of Metascreen Testing Platforms
Parameter | GC/MS | MS/MS |
---|---|---|
Newborn specimen collected | Urine:
|
Blood:
|
No. of metabolic disorders ("IEMs")that can be detected and quantified | 100+ IEMs from 9 groups of IEMs
|
40+ IEMs from 3 groups of IEMs
|
Biomarker, i.e. no. of analyte profiles used | Multiple markers used: Highly specific, definitive interpretation from one single test |
Mostly single marker used: Non-specific, ambiguous – 2nd tier testing required |
Time to diagnosis | Faster: From screening-cum-confirmation to diagnosis |
Slower: From screening to confirmation then finally to diagnosis |
Further confirmation required | Screening and confirmation from one single test, though occasionally requires further confirmation via:
|
Requires confirmatory test via:
|
Throughput | Approximately 15 minutes per sample: Total throughput of about 60 – 90 samples per machine in one day |
Approximately 2 minutes per sample: Total throughput of about 500 samples per machine in one day thus better for mass screening |
Interference |
|
Certain drugs and exogenous chemicals can interfere with acylcarnitine profile analysis e.g. valproic acid, cefotaxime, dextrose |